China Biotech Services Holdings Ltd. has announced a proposed issue of convertible bonds under a specific mandate. The company entered into a conditional subscription agreement with Wealth Strategy Holding Limited on 29 December 2025, under which Wealth Strategy Holding Limited will subscribe to convertible bonds in an aggregate principal amount of USD 35 million. The initial conversion price is set at HK$0.66 per conversion share, subject to adjustments. Completion of the subscription is conditional upon shareholder approval at a special general meeting and compliance with the requirements of the GEM Listing Rules. The proceeds are expected to support the company's business development and strategic initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Biotech Services Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11969870), on December 29, 2025, and is solely responsible for the information contained therein.